Issues and challenges in the development of pneumococcal protein vaccines

Expert Review of Vaccines

Volumn 11, Issue 3, 2012, Pages 279-285

  Ginsburg, Amy Sarah ^a   Nahm, Moon H ^b   Khambaty, Farukh M ^c   Alderson, Mark R ^a  

^a PATH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

animal models; pneumococcal vaccine; protein; Streptococcus pneumoniae

Indexed keywords

CYTOKINE; IC 47; MENINGOCOCCUS VACCINE; MYOSIN; PNEUMOCOCCAL SURFACE ADHESIN PROTEIN A; PNEUMOCOCCUS CONJUGATE VACCINE; PNEUMOCOCCUS CONJUGATE VACCINE 7; PNEUMOCOCCUS HISTIDINE TRIAD PROTEIN D; PNEUMOCOCCUS PROTEIN VACCINE; PNEUMOCOCCUS SURFACE PROTEIN A VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE RRGB; PNEUMOLYSIN; SERINE THREONINE KINASE PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE; WHOLE CELL VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CONSENSUS; CYTOKINE PRODUCTION; DRUG SAFETY; HEALTH PROGRAM; HUMAN; INVASIVE PNEUMOCOCCUS DISEASE; LICENSING; MEDICAL RESEARCH; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NON PROFIT ORGANIZATION; NONHUMAN; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEPSIS; SEQUENCE HOMOLOGY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH ORGANIZATION;

ANIMALS; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, SUBUNIT; VIRULENCE FACTORS;

EID: 84859053414     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.5     Document Type: Review

References (23)

1. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693), 893-902 (2009). Comprehensive global analysis estimating country-specific incidence of serious pneumococcal cases and deaths in children younger than 5 years.
2. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16(3), 217-225 (2010).
3. Cole R. Treatment of pneumonia by means of specific serums. JAMA 61(9), 663-666 (1913).
4. Whitney CG, Farley MM, Hadler J et al. Decline ininvasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348(18), 1737-1746 (2003).
5. Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27(52), 7257-7269 (2009).
6. Centers for Disease Control and Prevention (CDC). Licensure of a13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 59(9), 258-261 (2010).
7. Hennessy TW, Bulkow LR, Hammitt LL et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784-1792 (2007). Clearly demonstrates replacement invasive pneumococcal disease with non-PCV-7 serotypes among Alaska native children. The demonstration of replacement invasive pneumococcal disease emphasizes the importance of development of new pneumococcal vaccines that are serotype independent.
8. + T cells and IL-17A in protection of mice against pneumococcal nasopharyngeal carriage that may have important implications for pneumococcal protein vaccine development.
9. Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367(9512), 740-748 (2006).
10. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8(11), 1479-1500 (2009).
11. Briles DE, Hollingshead SK, King J et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182(6), 1694-1701 (2000).
12. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 10, 4 (2010).
13. Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10(1), 108-115 (2003).
14. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), e408-e413 (2005).
15. Van Gils EJ, Veenhoven RH, Hak E et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302(2), 159-167 (2009).
16. Frazao N, Sa-Leao R, de Lencastre H. Impact of asingle dose of the 7-valent pneumococcal conjugate vaccine on colonization. Vaccine 28(19), 3445-3452 (2010).
17. Target Product Profile (TPP) for the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines. www.who.int/immunization/sage/target-product- profile.pdf
18. WHO Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. www.who.int/biologicals/areas/vaccines/pneumo/ Pneumo-final-23APRIL-2010. pdf
19. Research Funding. Maryland: National Institutes of Health; c2010 [updated 2010 Dec 22; cited 2010 Dec 22]. http://funding.niaid.nih.gov/ncn/budget/ default.htm
20. Resources for Researchers. Maryland: National Institutes of Health; c2010 [updated 2010 Dec 22; cited 2010 Dec 22]. www.niaid.nih.gov/labsandresources/ resources/dmid/Pages/default.aspx
21. Bacterial Respiratory Pathogen Reference Laboratory. University of Alabama at Birmingham; c2010 [updated 2010 Dec 22; cited 2010 Dec 22]. www.vaccine.uab.edu
22. About Research and Development Contracts. National Institutes of Health; c2010 [updated 2010 Dec 22; cited 2010 Dec 22]. http://funding.niaid.nih.gov/ researchfunding/contract/pages/about.aspx
23. PATH's pneumococcal vaccine project. www.path.org/projects/pneumococcal- protein-vaccine-project.php